Dogwood Therapeutics (DWTX) Share-based Compensation (2020 - 2025)
Dogwood Therapeutics (DWTX) posted quarterly Share-based Compensation of $157860.0 for Q4 2025, up 68.29% year-over-year from $93802.0 in Q4 2024, and up 226.96% quarter-over-quarter from $48281.0 in Q3 2025.
Dogwood Therapeutics (DWTX) Share-based Compensation (2020 - 2025) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Share-based Compensation for 6 consecutive years, with $157860.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Share-based Compensation rose 68.29% year-over-year to $157860.0; the TTM figure through Dec 2025 stood at $355642.0 (down 25.29% YoY), while the FY2025 annual figure was $355642.0, down 25.29% from the prior year.
- Share-based Compensation improved to $157860.0 in Q4 2025 per DWTX's latest filing, from $48281.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $164266.0 in Q3 2022 and bottomed at $24825.0 in Q1 2021.
- Historically, Share-based Compensation has averaged $117858.8 across 5 years, with a median of $134431.5 in 2021.
- Annual changes were most pronounced in 2021 — Share-based Compensation plunged 97.57% — and 2022, when it soared 431.34%.
- Dogwood Therapeutics' Share-based Compensation stood at $131906.0 in 2021, then advanced by 13.36% to $149530.0 in 2022, then retreated by 0.82% to $148306.0 in 2023, then slumped by 36.75% to $93802.0 in 2024, then jumped by 68.29% to $157860.0 in 2025.
- Business Quant data shows DWTX's Share-based Compensation at $157860.0 in Q4 2025, $48281.0 in Q3 2025, and $65027.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | - |
| 10 | Dogwood Therapeutics | 82.25 Mn | 82.25 Mn | - | 5.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 157,860.00 |
| Dec 31, 2025 | 157,860.00 |
| Sep 30, 2025 | 48,281.00 |
| Sep 30, 2025 | 48,281.00 |
| Jun 30, 2025 | 65,027.00 |
| Jun 30, 2025 | 65,027.00 |
| Mar 31, 2025 | 84,474.00 |
| Mar 31, 2025 | 84,474.00 |
| Dec 31, 2024 | 93,802.00 |
| Dec 31, 2024 | 93,802.00 |
| Sep 30, 2024 | 94,302.00 |
| Sep 30, 2024 | 94,302.00 |
| Jun 30, 2024 | 148,948.00 |
| Jun 30, 2024 | 148,948.00 |
| Mar 31, 2024 | 138,969.00 |
| Mar 31, 2024 | 138,969.00 |
| Dec 31, 2023 | 148,306.00 |
| Dec 31, 2023 | 148,306.00 |
| Sep 30, 2023 | 148,305.00 |
| Sep 30, 2023 | 148,305.00 |